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Mass vaccination campaigns with the oral poliovirus vaccine targeting children aged <5 years are a critical compo-
nent of the global poliomyelitis eradication effort. Monitoring the coverage of these campaigns is essential to allow
corrective action, but current approaches are limited by their cross-sectional nature, nonrandom sampling, reporting
biases, and accessibility issues. We describe a new Bayesian framework using data augmentation and Markov chain
Monte Carlo methods to estimate variation in vaccination coverage from children’s vaccination histories investigated
during surveillance for acute flaccid paralysis. We tested the method using simulated datawith at least 200 cases and
were able to detect undervaccinated groups if they exceeded 10% of all children and temporal changes in coverage of
±10% with greater than 90% sensitivity. Application of the method to data from Pakistan for 2010–2011 identified
undervaccinated groups within the Balochistan/Federally Administered Tribal Areas and Khyber Pakhtunkhwa re-
gions, as well as temporal changes in coverage. The sizes of these groups are consistent with themultiple challenges
faced by the program in these regions as a result of conflict and insecurity. Application of this newmethod to routinely
collected data can be a useful tool for identifying poorly performing areas and assisting in eradication efforts.
acute flaccid paralysis; Bayesian analysis; oral poliovirus vaccine; poliomyelitis; vaccination coverage
Abbreviations: AFP, acute flaccid paralysis; CrI, credible interval; FATA, Federally Administered Tribal Areas; KP, Khyber
Pakhtunkhwa; OPV, oral poliovirus vaccine; SIA, supplementary immunization activity.
Immunization is a proven health intervention that directly
protects vaccinated individuals and the remaining popula-
tion through herd immunity. Vaccination may be delivered
through routine immunization or supplementary immunization
activities (SIAs), including mass immunization campaigns.
SIAs are carried out where routine immunization is known
to be poor, where the vaccination policy has recently changed
and the immunization status of the target population needs
to be updated, or as part of an accelerated disease control
effort such as those made to eliminate or eradicate speciﬁc
pathogens (1). Routine vaccination of children against polio-
myelitis is supplemented with mass immunization campaigns
using the oral poliovirus vaccine (OPV) in many countries as
part of the Global Polio Eradication Initiative (http://www.
polioeradication.org/).
The coverage of an SIA, deﬁned as the proportion of the
target population successfully vaccinated by the end of the
campaign, is an important quantity to know but is difﬁcult
to directly estimate. A crude estimate of coverage often used
is the number of vaccine doses distributed divided by the size
of the target population. This administrative coverage is
error-prone, as it assumes no wastage of vaccines, ignores in-
dividuals receiving multiple doses, and relies on accurate es-
timation of the size of the target population (2). Amore recent
method of analysis combines stock data, the size of target
populations, and World Health Organization estimates of
coverage to determine heterogeneity in coverage, but it still
requires accurate estimates of the target population size (3).
Cross-sectional health surveys collect information on children’s
immunization histories based on parental recall, but these are
infrequent and have not included some of the key areas for the
poliomyelitis eradication program. Postcampaign surveys are
often carried out to assess coverage after mass immunization;
children are ﬁnger-marked when vaccinated, and the proportion
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of ﬁnger-marked children is estimated several days later by
an independent team surveying households and local gath-
ering places (4). These surveys are not reliant upon knowl-
edge of the target population size and are considered more
accurate than stock estimates. However, postcampaign sur-
veys are expensive, are prone to an upward bias of estimates
(because the surveyors may use the same community map
as the vaccinators), and in insecure areas may be impossible
to carry out (since July 2012, postcampaign surveys have
been cancelled in some areas of Pakistan due to security
concerns (5)).
Poliomyelitis persists in Pakistan because of a variety of
issues: managerial and operational problems, active conﬂict
and inaccessibility, and failure to identify and access at-risk
but hard-to-reach populations (6). These issues have resulted
in populations with low vaccine coverage and in some cases a
suggestion that some groups of children are consistently less
likely to be vaccinated during campaigns compared with the
general population (6).We refer to these groups of children as
“persistently undervaccinated groups.” An undervaccinated
group may include children whose accessibility by vaccina-
tion teams is limited or who are reachable but whose caregiv-
ers choose not to have them vaccinated.
Mass campaigns with OPV typically target several million
children over a period of 3–5 days, and detailed records of
activities are available for most countries at the second ad-
ministrative (district) level. Additionally, acute ﬂaccid paral-
ysis (AFP) is investigated in more than 100,000 children
globally every year; most cases of AFP (at least 95%) result
from causes other than poliovirus infection (7). These chil-
dren undergo a detailed clinical and epidemiologic investiga-
tion, which includes questions posed to their caregiver on the
number of OPV doses received through routine immuniza-
tion and SIAs (and results are usually reported separately).
Previous estimates of vaccination coverage from these data
(referred to as crude estimates) have simply divided the re-
ported number of SIA doses received by childrenwithAFP by
the number of SIAs occurring during their lifetimes in their
districts of residence (8). However, because these crude esti-
mates are typically summarized for children within a rela-
tively wide age range (e.g., <2 years of age), they represent
an average over a period of a few years, diluting any rapid
changes in the coverage of campaigns.
Here we describe a novel statistical method that permits es-
timation of vaccination campaign coverage over time from
routinely collected AFP data and apply it to surveillance
data from Pakistan.
METHODS
Data
The clinical symptoms of poliomyelitis are characterized
by the rapid onset of weakness, typically but not exclusively
in the lower limbs, with involuntary muscle paralysis but no
loss of sensation, progressing eventually to spasticity over the
longer term—collectively known as AFP. AFP is not exclu-
sively caused by infection with poliovirus but may be caused
by a wide range of conditions, such as Guillain-Barré syn-
drome, trauma, and infection with other enteroviruses (9).
Surveillance for poliomyelitis is based on reporting of AFP
by health-care providers and detailed investigations (7). Two
stool samples are collected within 14 days of the onset of pa-
ralysis and more than 24 hours apart and are tested for the
presence of poliovirus. At the time of investigation, an inter-
view with the parents/caregivers of the child is conducted
where information on the reported number of OPV doses re-
ceived through routine immunization and SIAs is sought.
Cases in which 2 adequate stool samples are found to be neg-
ative for both wild-type and vaccine-related polioviruses are
deﬁned as nonpolio AFP.
Health-care-seeking by caregivers means that children
with AFP are frequently captured by the surveillance net-
work. At least 1 case of nonpolio AFP is expected annually
in a population of 100,000 children aged <15 years (in high-
risk areas, the target rate is 2 cases per 100,000 children aged
<15 years (10)). In many areas with poliomyelitis cases, AFP
reporting exceeds 1 per 100,000 children aged <15 years as a
result of enhanced surveillance and a high incidence of en-
terovirus infections and other causes of AFP. This means
that cases of AFP are typically reported from most parts of
a country and that areas with conditions favoring poliovirus
transmission are often oversampled (8, 11).
Nonpolio AFP data from children born between January
2008 and December 2011 with onset of paralysis between
January 2010 and December 2011, a subset of data previ-
ously described (8), were used in this analysis. Children with-
out sufﬁcient information on age, date of birth, district of
residence, or OPV vaccination history were excluded. For
each case of nonpolio AFP, the number of OPV doses re-
ceived through SIAs, as reported by the caregiver, was com-
pared with the SIA calendar for the district of residence. Data
from Pakistan were grouped into the following regions:
1) Balochistan and the Federally Administered Tribal Areas
(FATA); 2) Khyber Pakhtunkhwa (KP); 3) Sindh; and
4) Punjab and Islamabad (observations from Gilgit-Baltistan,
Azad Jammu, and Kashmir were not included in the analysis,
owing to the small number of eligible cases (n = 20)). The in-
cidence of reported AFP was compared with census-based
population estimates to determine the geographic representa-
tiveness of these data (12, 13).
We applied methods typically used to assess campaign
success and compared them with our new approach (10, 14).
For each region, we report the proportions of children aged 6–
23 months with nonpolio AFP who received no OPV doses
and more than 3 doses (with 95% bootstrapped conﬁdence
intervals). Children in this age group are of special interest
to the Global Polio Eradication Initiative because they consti-
tute the majority of cases of poliomyelitis (8). Crude cover-
age estimates are derived by dividing the reported number of
OPV doses by the number of SIA campaigns and are reported
by region and year (8). This crude estimate accounts for the
increase in the number of reported doses with age, because
the denominator also increases with age and reﬂects an aver-
age of past campaign coverage over a 2-year time frame.
New methods
We report a new method for estimating vaccination cam-
paign coveragewhichmakes full use of the vaccination history
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of each child with AFP and the detailed SIA calendar (Fig-
ure 1). Campaign-speciﬁc estimates of vaccination coverage
and identiﬁcation of persistently undervaccinated groups are
possible by making use of shared information among chil-
dren with AFP who are exposed to common SIAs.
For example, child number 6 in Figure 1 was exposed to 3
SIAs and had 2 of those SIAs in common with child number
7. Differences in the number of reported doses provide infor-
mation about the SIA that was not shared, while the average
provides information about the SIAs the two children had
in common. Because child 6 was reported to have received
1 dose of OPV and child 7 was reported to have received no
doses, this suggests that the nonshared SIA had good cover-
age and the 2 shared SIAs had poor coverage.
To estimate vaccination campaign coverage from nonpolio
AFP data, we developed a set of simple models of coverage
that correspond to program experience, allowing for heteroge-
neity in space and time. We considered the effect of caregiver
error in the recall and reporting of the number of OPV doses
received by children with AFP by allowing the reported num-
ber of doses to differ from the actual number of doses received.
In our approach, each individual i present in the data is
reported to have received xi doses of OPV, and from the vac-
cination calendar we calculate the expected number of SIAs
(si) from birth to the onset of paralysis. We assume that the
reported number of doses is distributed around the actual
number of doses (yi) according to a discretized lognormal
distribution with a small coefﬁcient of variation (α) to capture
inaccuracies in the reported doses. We assume that the actual
number of doses is binomially distributed, with the expected
SIAs representing the number of trials and the probability of
vaccination corresponding to campaign coverage. The propor-
tion of children with AFP vaccinated during a campaign may
vary between campaigns, even for campaigns with the same
coverage, although this variation will be relatively small (ap-
proximately <5%) for typical estimates of coverage if the num-
ber of children included in the AFP sample is reasonably large
(approximately >50). Full details on the methods are given in
theWebAppendix (available at http://aje.oxfordjournals.org/).
Each model of vaccination coverage represents a differ-
ent hypothesis about the cause of variability. The simplest
homogeneous model assumes a constant probability (ρ) of
being vaccinated during each campaign. To account for new
initiatives or limitations in accessibility, the homogeneous-
temporal model assumes a step change in vaccination cover-
age at a speciﬁc time point. Persistently undervaccinated
groups are accounted for in the heterogeneous model, where
the population is divided into 2 groups that differ in terms of
their size and coverage. These groups may reside in the same
geographic region but capture problems with inaccessibility or
vaccine refusal. In this model, each child is arbitrarily assigned
an additional variable describing his/her membership in either
group (undervaccinated or not), and this variable is estimated
using Markov chain Monte Carlo methods. The size of the un-
dervaccinated group is estimated a posteriori from this aug-
mented variable. The heterogeneous-temporalmodel accounts
for both temporal changes in coverage and the presence of un-
dervaccinated groups. Other models may bewritten as required
to formally assess speciﬁc programmatic questions about
changes in campaign coverage over time and/or location.
Application to simulated and real AFP data
The parameters of each model consist of the coefﬁcient of
variation and the coverage parameters, summarized by θ = {ρ,
α}. The posterior probability of the model, given the data, is
PrðθjX;Y ;SÞ∝ LðθjX;Y ;SÞgðθÞ ¼ PrðY jθÞPrðX;SjYÞgðθÞ;
where L(θjX, Y, S) is the likelihood of observed and augmented
data, given the model parameters, and g(θ) is the prior distribu-
tion of the model parameters.We calculated the posterior prob-
ability using the output from the Markov chain Monte Carlo
methods, with each chain run for 2 million iterations with an
initial burn-in of 500,000 iterations and thinned to every 100th
iteration, leading to a ﬁnal posterior sample of size 2,000 (15).
Three chainswere compared to ensuremodel convergence. The
4modelswere compared using a rescaled deviance information
criterion, which accounts for the ﬁt of the model to the data and
penalizes models with more parameters (16).
We used simulated data to assess the performance of our
approach and the accuracy of model selection. We performed
100 simulations for each scenario (corresponding to the
homogeneous, heterogeneous, homogeneous-temporal, and
heterogeneous-temporal models, respectively, with varying
parameter values), with a sample size of 200 children with
AFP, broadly corresponding to the minimum annual sample
sizes observed in each region of Pakistan. Each child was ex-
posed to 15 sequential SIAs out of a potential 40 in the time
series. These parameters were then estimated using ourmethod,
SIA
Birth Paralysis
Reported
No. of Doses
1
3
1
0
2
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0
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Figure 1. Schematic diagram of acute flaccid paralysis (AFP) data
and the novel method the authors used for estimating oral poliovirus
vaccine (OPV) immunization coverage in Pakistan. Lines representing
the life histories of 7 children up to the onset of AFP are shown. The
arrows at the top of the figure correspond to supplementary immuniza-
tion activity (SIA), and the X’s and diamonds for each child indicate
whether the child was vaccinated during each SIA. Differences in
the reported numbers of OPV doses received through SIA between
children with AFP can be used to infer SIA coverage and is the
basis for the new method described in the text (see Methods). In
this example, 28.6% of children are reported to have received zero
doses of OPV and no children are reported to have received more
than 3 doses of OPV. In contrast to the new method, these summary
statistics do not account for the age of each child, exposure to different
numbers of SIAs, or errors in recall.
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with model choice informed by the rescaled deviance informa-
tion criterion.
We applied the method to AFP data from 2010–2011 for
each region of Pakistan, and the ﬁts of different vaccination
models were compared using the rescaled deviance informa-
tion criterion. Where there was evidence for a persistently
undervaccinated group, estimates of the sizes of undervacci-
nated populations were explored for smaller geographic
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Figure 2. Age distribution of children with acute flaccid paralysis (AFP) not caused by poliomyelitis (nonpolio AFP) reported in Pakistan during
2010–2011 and their reported vaccination histories, by age. A) Age distribution; B) mean number of supplementary immunization activities (SIAs)
experienced by children aged <2 years in different regions, by 6-month age group (black squares), together with the number of doses of oral po-
liovirus vaccine (OPV) they were reported to have received (boxes and whiskers). The boxes show the median value (black line) and interquartile
range of the data, while the whiskers correspond to 1.5 times the interquartile range.
Table 1. Surveillance Data on Cases of Acute Flaccid Paralysis (AFP) Not Caused by Poliomyelitis (Nonpolio AFP)
With Onset of Paralysis Between 2010 and 2011 and Related Demographic Characteristics for Specified Regions of
Pakistan
Region
Demographya Surveillance Datab
Total
Population
(N)
No. of Children
Aged <15
Years
No. of Nonpolio
AFP Cases
(2010–2011)
Annual Rate of
Nonpolio AFP
(per 100,000
Children Aged <15
Years)
Median Age of
Nonpolio AFP
Cases,
months
No. of Children
Aged
<24 Months
Balochistan/
FATA
12,325,103 4,363,086 612 7.0 39.4 273
KP 22,393,497 7,927,298 1,656 10.4 44.4 567
Sindh 38,537,646 13,642,327 2,315 8.5 49.3 1,324
Punjab 93,219,441 32,999,682 4,194 6.4 49.1 589
Other areas 7,117,313 2,519,529 101 2.0 48.1 —c
Total 173,593,000 61,451,922 8,878 7.2 47.7 2,753
Abbreviations: AFP, acute flaccid paralysis; FATA, Federally Administered Tribal Areas; KP, Khyber Pakhtunkhwa.
a Total population based on the United Nations estimate for 2011 and regional breakdown provided by the most
recent available census (1988).
b Surveillance is regarded as sufficient when at least 2 cases of nonpolio AFP are detected per 100,000 population
aged <15 years per year.
c Observations from Gilgit-Baltistan, Azad Jammu, and Kashmir were not included in the analysis, owing to the
small number of eligible cases (n = 20).
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areas. For estimates of the number of children with AFP in
the undervaccinated group, we included the additional un-
certainty in the 95% credible intervals when extrapolating
from the AFP sample to the general population by assum-
ing that children with AFP represented a random sample
from the general population.
The analysis was carried out with R statistical software, ver-
sion 3.0.1 (R Foundation for Statistical Computing, Vienna,
Austria). Institutional ethics approval was not sought, since
this was a retrospective study. The databases we used are ano-
nymized and free of personally identiﬁable information.
RESULTS
Summary of AFP data from Pakistan
A total of 10,857 cases of AFP were reported in Pakistan
between 2010 and 2011. Of these, 1,979 cases were not
deﬁned as nonpolio AFP, because they were classiﬁed as
cases of poliomyelitis or cases compatible with poliomyelitis
or because stool samples and information on the child’s age
were not available; these observations were excluded from
the analysis. In the remaining 8,878 nonpolio AFP cases, the
average rate was 7.2 cases per 100,000 population under 15
years of age, where 70.6% of cases were in children under 5
years of age (Figure 2A). Health authorities were notiﬁed of
nonpolio AFP cases from across Pakistan, with a higher rate
in Sindh and KP compared with other regions and a small
amount of variation in the average age at onset of paralysis
(Table 1). Of these cases, 2,753 children (31.0%) were born
after January 1, 2008, and were under age 24 months at the
time of AFP onset; details from these cases were used to infer
vaccination coverage. The average number of SIAs children
were exposed to increased with age and varied by region, re-
ﬂecting differences in the vaccination calendar (Figure 2B).
The number of reported OPV doses also increased with age,
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Figure 3. Summary statistics and estimates of oral poliovirus vaccine (OPV) immunization campaign coverage for specified regions of Pakistan,
2010–2011. The upper panels show the percentages of nonpolio acute flaccid paralysis (AFP) cases among children aged 6–23 months who were
reported to have received more than 3 doses of OPV (A) and zero doses of OPV (B). Panel C presents crude estimates of vaccination coverage
obtained by dividing the reported number of OPV doses by the number of immunization campaigns experienced by each child. Note that the upper
limit can exceed 100%, reflecting error reporting. Panel D presents estimates of vaccination coverage obtained using the newmethod. In Balochistan/
Federally Administered Tribal Areas (FATA) and Khyber Pakhtunkhwa (KP), the heterogeneous model gave the best fit, where 34% and 43% of
children, respectively, were estimated to be in the undervaccinated group. Coverage in the undervaccinated group is shown by the black bars. The
open diamonds indicate average coverage across the 2 groups in the heterogeneous model. The error bars in panels A–C indicate the 95% con-
fidence intervals, and the error bars in panel D show the 95% credible intervals from the best-fit model.
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and the variability in dose reporting was larger in Balochistan/
FATA and KP when compared with Sindh and Punjab.
The proportion of children aged 6–23months in Balochistan/
FATA who received more than 3 doses of OPV was 65%
(95% conﬁdence interval: 55, 74), while this estimate was
higher in other regions (Figure 3A). Consistent with these re-
sults, the proportion of children who were reported to have
received zero doses was higher in Balochistan/FATA (Fig-
ure 3B). Crude estimates suggested lower coverage in the
Balochistan/FATA region (Figure 3C); in 2010, the crude
estimate was 51.3% (95% conﬁdence interval: 44.5, 57.8).
Crude coverage estimates in KP were similar in value to the
Punjab region, and therewas an apparent increase in coverage
in Sindh among children with nonpolio AFP in 2011 when
compared with those who were paralyzed in 2010.
Application of novel method to simulated data
The novel method correctly identiﬁed the homogeneous
model for data simulated under this model for a majority of
simulations, and it provided accurate and unbiased estimates
of coverage (see Table 2; full results are given in Web Table 1).
Themethodwas also able to detect persistently undervaccinated
groups in at least 89% of simulations under the heterogeneous
model for a variety of realistic parameter values (Table 2 and
Figure 4A). Estimates of vaccination coverage in both the “cov-
ered” and undervaccinated groups were accurate and precise,
and the sensitivity and speciﬁcity for detection of undervacci-
nated groups were above 90% in most simulations. Where the
sensitivity or speciﬁcitywas below 90%, the estimated coverage
in the undervaccinated group was higher than simulated, and a
larger proportion was estimated in the undervaccinated group.
Temporal changes in coverage were also detected with
good accuracy in the simulations (Table 3 and Figure 4B). Ab-
solute changes in coverage that were greater than 10% were
detected in at least 89% of simulations, and the 95% credible
intervals of the estimated values generally included the sim-
ulated value. In simulations where undervaccinated groups
were included in addition to temporal changes, model selec-
tion performed optimally when the absolute difference in
coveragewasgreater than20%.Theestimatesofcoveragefrom
the heterogeneous-temporal model ﬁtted the simulated data
well and maintained a high sensitivity and speciﬁcity for
detecting undervaccinated groups. Where the simulated dif-
ference in temporal coverage was less than 20%, either the
heterogeneous model or the homogeneous-temporal model
was selected, suggesting that it was possible to detect under-
vaccinated groups or a change in coverage, but not both. Over-
all, coverage was underestimated, because the percentage of
individuals in the undervaccinated group was overestimated.
Applying the new methods to the Pakistan data set
The heterogeneous-temporal model had the best ﬁt to the
data from Balochistan/FATA and KP, while the homogeneous-
temporal model had the best ﬁt to Punjab and Sindh (Table 4).
There was evidence in all regions of a change in SIA coverage
in 2011 compared with previous years (2008–2010), and with-
in Balochistan/FATA and KP there was evidence of a groupT
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that was persistently undervaccinated in comparison with the
general population.
Within Balochistan/FATA and KP, a majority of the target
population (children aged <5 years) was estimated to have
vaccination coverage above 50%, but 34% (95% credible
interval (CrI): 28, 41) were undervaccinated in Balochistan/
FATA and 43% (95% CrI: 37, 49) were undervaccinated in
KP (Table 3, Figure 3D). When the 2 regions were divided
into smaller areas, the Mohmand and Bajour districts (re-
ferred to as Mohmand) had a signiﬁcantly lower proportion
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Figure 4. Model estimates for oral poliovirus vaccine coverage and actual simulated coverage. A) Data simulated under the heterogeneousmodel
with 40% in the undervaccinated group; B) data simulated under the homogeneous-temporal model. Estimates are shown by the triangles and
squares, and the actual value in each group or time period is shown by the horizontal lines. Results from 50 simulations are shown.
Table 3. Performance of the Authors’Novel MethodWhenApplied to Acute Flaccid Paralysis Data Simulated Under a Homogeneous-Temporal or
Heterogeneous-Temporal Model of Oral Poliovirus Vaccine Coveragea
Vaccination Model and Average
Coverage Used in Simulations, %
Best-Fit Model Based on
rDIC (% of Simulations)b
Estimated Average
Vaccination Coverage, %
Time Period 1
(12 Months)
Time Period 2
(12 Months) Homogeneous Heterogeneous
Homogeneous-
Temporal
Heterogeneous-
Temporal
Time Period 1 Time Period 2
Median 95%CrI Median 95%CrI
Homogeneous-Temporal Model
80 40 0 0 98 2 80.1 77.3, 82.9 40.4 37.3, 43.5
80 50 0 0 96 4 80.2 77.3, 83.1 50.3 47.1, 53.5
80 60 0 0 95 5 80.0 77.1, 82.9 60.1 56.8, 63.3
80 70 5 3 89 3 80.4 77.4, 83.2 70.1 66.8, 73.2
80 90 1 0 98 1 79.9 77.0, 82.6 89.9 87.1, 92.5
Heterogeneous-Temporal Model c
52 28 0 0 0 100 45.1 41.9, 48.3 24.9 22.0, 27.8
52 34 0 0 0 100 44.9 42.1, 47.8 29.8 26.9, 32.8
52 40 0 0 0 100 44.5 41.8, 47.1 34.4 31.6, 37.2
52 46 0 37 31 32 44.5 42.0, 47.0 39.8 37.1, 42.5
52 58 0 13 35 52 44.3 41.8, 46.7 49.3 46.8, 51.7
Abbreviations: CrI, credible interval; rDIC, rescaled deviance information criterion.
a These models assume that coverage varies between 2 time periods. In addition, in the heterogeneous-temporal model, a proportion of the
children with acute flaccid paralysis are assumed to come from an undervaccinated group, as for Table 2 (see Methods for details).
b Underlined values correspond to the correct model choice.
c Assuming that 40% of children are in an undervaccinated group with 10% coverage that does not change over time.
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of undervaccinated children than the remaining districts
within the Balochistan/FATA region (Figure 5). Central KP
(consisting of 8 districts, including Peshawar and Kohat) was
estimated to have an undervaccinated group that was signiﬁ-
cantly larger than those of other districts within the region,
similar to that reported for the Balochistan/FATA region.
Within Punjab, coverage was estimated to be 76.7% (95%
CrI: 75.6, 77.9) in 2010, with no change in the median value
in 2011 but an increase in uncertainty and/or variability
(median, 76.7%; 95% CrI: 73.7, 79.9). Within Sindh, cov-
erage was 64.7% (95% CrI: 62.3, 67.0) in 2010, and it in-
creased to 83.8% (95% CrI: 78.2, 89.3) in 2011. There was
Table 4. Estimated Coverage of Oral Poliovirus Vaccine Immunization Campaigns in Pakistan Between 2008 and
2011 and the Size of the Undervaccinated Group in Specified Regions of Pakistan
Region and Year
of SIAs
Total No. of
Nonpolio
AFP Cases
Estimated
Vaccination
Coveragea, %
Estimated
Coverage in the
Undervaccinated
Group, %
Estimated Size of
Undervaccinated Group,
% of Population
Median 95% CrI Median 95% CrI Median 95% CrI
Balochistan/FATA
2008–2010 273 64.5 60.8, 68.4 11 7.5, 15.7 34.2 28, 40.6
2011 79.4 71.9, 86.6 5.9 2.4, 10.4 34.2 28, 40.6
KP
2008–2010 567 94.3 91.6, 97.3 61.6 58.2, 64.5 42.9 37.1, 48.8
2011 87.1 79.9, 94.3 39.2 26.4, 49.5 42.9 37.1, 48.8
Punjab
2008–2010 1,304 76.7 75.6, 77.9
2011 76.6 73.7, 79.9
Sindh
2008–2010 589 64.7 62.3, 67
2011 83.8 78.2, 89.3
Abbreviations: AFP, acute flaccid paralysis; CrI, credible interval; FATA, Federally Administered Tribal Areas; KP,
Khyber Pakhtunkhwa; SIAs, supplementary immunization activities.
a Excluding children in the undervaccinated group, where the best-fit model indicates heterogeneous coverage.
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Figure 5. Sizes and locations of persistently undervaccinated groups of children under age 5 years in Pakistan, 2010–2011. Data on cases of acute
flaccid paralysis (AFP) were aggregated for groups of districts (A). The estimated proportions of children persistently undervaccinated are shown by the
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no evidence of an undervaccinated group within these
regions.
DISCUSSION
We have described a new method for estimating vaccina-
tion campaign coverage from routinely collected AFP data
that allows the identiﬁcation of persistently undervaccinated
children as well as temporal changes in coverage while ac-
counting for errors in reporting. Simulated data suggested
that with limited reporting error, trends in vaccination cov-
erage and the presence of undervaccinated groups can be
accurately identiﬁed when the sample size exceeds 200. Het-
erogeneity in coverage from the presence of undervaccinated
groups is epidemiologically important and impossible to as-
sess using other methods. Application of these methods to
Pakistan has illustrated that a large percentage of the Pakistan
population is persistently undervaccinated and that coverage
had changed in 2011 when compared with 2008–2010.
While current assessments of SIA performance (the pro-
portions of children with more than 3 OPV doses, zero doses,
andcrudecoverageestimates)are informative, theymasksome
of the heterogeneity present in the data and represent an av-
erage across children of different ages who have been exposed
to different SIAs. It is clear from the crude analyses and our new
model that Balochistan/FATA has suboptimal coverage and a
persistently undervaccinated group of children, but the het-
erogeneity in coverage within KP was not apparent using the
crude analyses, since theproportionof childrenwithmore than
3 doses was high and the proportion of zero-dose children
was low. A high proportion of children (37%, 95%CrI: 37, 49)
were estimated to be in a persistently undervaccinated group in
central KP, with coverage of only 39.1% during SIAs in 2011.
This highlights known issues with maintaining high vaccina-
tion coverage, such as in Peshawar, where there have been se-
curity concerns and where up to 20% of children were known
to be inaccessible in 2009 (5). In Balochistan/FATA, inacces-
sibility is reported to be as high as 30% (5), which corresponds
well to our estimates of the proportion in the persistently under-
vaccinated group (Table 4).
The existence of large undervaccinated groups in KP and Ba-
lochistan/FATA during 2008–2011 points to the multiple chal-
lenges the Global Polio Eradication Initiative has faced in
Pakistan, including operational and managerial issues, lack of
political and public support, natural disasters, inaccessibility,
and conﬂict (17). While many of these challenges are being ad-
dressed, there have been serious concerns about the safety of the
vaccination teams in some areas of Pakistan because of attacks
that have occurred since 2012 (5). Furthermore, a ban on vacci-
nation in NorthWaziristan has led to a major epidemic of polio-
myelitis in FATA, and infection has spread to other parts of
Pakistan and Afghanistan (18). Vaccination operations are re-
viewed by managers, and engagement with local communities
and leaders occurs to help determine the reasons for poor cov-
erage and work towards local solutions. Accurate estimates of
vaccination coveragemust form a key part of poliomyelitis erad-
ication, and estimates will be updated beyond 2012 to support
programmatic assessments in Pakistan and other countries.
Our method suffers from a number of limitations. The AFP
dose reporting histories provide a relevant but convenient sam-
ple and may not fully represent all children who are targeted
during immunization campaigns in Pakistan. The number of
available AFP reports decreases as the spatial or temporal reso-
lution is increased. This can be addressed by aggregating dis-
tricts as in Figure 5 or by using spatial smoothing techniques
that share information between nearby districts (e.g., conditional
autoregressive modeling (19)). Large inaccuracies or bias in the
reporting of vaccination histories from children with AFP will
also prevent accurate estimation of SIA coverage using our
method. We accounted for a degree of recall error, but we
were unable to estimate the coefﬁcient of variation for this dis-
tribution without a tightly constrained prior, reﬂecting con-
founding between variability in reporting and variability in
coverage. We explored values for the coefﬁcient of variation
where the difference between the number of reported doses
and the number of actual doses received was no more than 4,
and within these limits the model was robust (Web Figure 1).
In a previous study carried out in India, Grassly et al. (20) ex-
amined recall error by repeating interviews with parents and
found that there was some recall error but no evidence of
bias. It would be advantageous to estimate recall error in popu-
lations using these and similar methods, as this would improve
the precision of model selection.
We were not able to explore variability in recall error be-
tween regions in addition to heterogeneity in vaccination cov-
erage because of the difﬁculties involved in identifying
children from undervaccinated groups when recall error is
large. However, the identiﬁcation of undervaccinated groups
located in Balochistan/FATA and KP is consistent with the ep-
idemiology of poliomyelitis in these regions, which continues
to be reported in speciﬁc areas despite good campaign cover-
age on average across the region. Further studies, such as cross-
sectional serological surveys, would be highly informative but
difﬁcult to implement because of the political instability in the
area. Finally, a potential source of error in our estimates would
be inaccuracies in the SIA calendar or long-term movement of
children between regions, such that they were not exposed to
the SIA reported for their district of residence. This would
have been mitigated to some degree by the fact that SIA cam-
paigns are often coordinated across regions.
Use of data augmentation techniques and Markov chain
MonteCarlomethods has enabled us to develop a novelmethod
for estimating vaccination coverage. Thismethodmay be a par-
ticularly useful programmatic tool for the late stages of the
Global Polio Eradication Initiative, as it enables identiﬁcation
of poorly performing areas, taking advantage of data that are
already routinely collected. Model validation using simulated
data has illustrated the circumstances in which the analysis
can correctly identify heterogeneity in coverage. Application of
thesemodels to surveillance data from Pakistan has highlighted
considerable temporal and spatial variability in coverage be-
tween regions and the presence of persistently undervaccinated
groups of children within certain key areas.
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